Logo

HYPD

Hyperion DeFi, Inc.

HYPD

Hyperion DeFi, Inc. • NASDAQ
$4.51 ▲ 6.37% (+0.27)
Market Cap $25.68 M
52w High $18.00
52w Low $0.85
Dividend Yield 0%
P/E -0.24
Volume 128.87K
Outstanding Shares 5.69M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $302.506K ▲ $2.968M ▼ $6.626M ▲ 2.19K% ▲ $0.26 ▲ $6.849M ▲
Q2-2025 $0 ▼ $8.278M ▲ $-8.691M ▼ 0% ▲ $-10.32 ▼ $-8.087M ▼
Q1-2025 $14.72K ▼ $3.045M ▼ $-3.484M ▲ -23.665K% ▲ $-4.09 ▲ $-2.902M ▲
Q4-2024 $28.093K ▲ $16.378M ▲ $-19.955M ▼ -71.031K% ▲ $-23.44 ▼ $-19.127M ▼
Q3-2024 $1.625K $7.201M $-7.888M -485.406K% $-8.8 $-6.998M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $8.223M ▲ $82.79M ▲ $12.035M ▼ $70.755M ▲
Q2-2025 $7.532M ▲ $55.66M ▲ $18.301M ▲ $37.359M ▲
Q1-2025 $3.935M ▲ $5.984M ▲ $15.698M ▼ $-9.714M ▲
Q4-2024 $2.121M ▼ $3.668M ▼ $16.764M ▼ $-13.096M ▼
Q3-2024 $7.188M $22.796M $19.077M $3.719M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $6.626M ▲ $-2.823M ▲ $-20.112M ▲ $23.626M ▼ $690.888K ▼ $-2.8M ▲
Q2-2025 $-8.691M ▼ $-3.447M ▲ $-45.523M ▼ $52.567M ▲ $3.597M ▲ $-48.97M ▼
Q1-2025 $-3.484M ▲ $-4.443M ▲ $0 $6.256M ▲ $1.814M ▲ $-4.443M ▲
Q4-2024 $-19.955M ▼ $-6.111M ▼ $0 ▲ $1.044M ▼ $-5.067M ▼ $-6.111M ▼
Q3-2024 $-7.888M $-5.944M $-1.623K $10.833M $4.887M $-5.945M

Five-Year Company Overview

Income Statement

Income Statement Hyperion DeFi is still in the “pre-revenue” phase. Over the last several years it has effectively generated no meaningful sales and has consistently posted operating and net losses. This pattern is typical of an early-stage, transition-phase business that is investing in strategy and infrastructure before having a proven, sustainable revenue model. The lack of revenue, combined with ongoing expenses, means profitability is not yet in sight and the business model is still unproven in financial terms.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small base of assets and cash and, most recently, negative shareholders’ equity. That signals accumulated losses have already eaten through the original capital buffer. There is some debt but not much of a tangible asset base behind it, which limits financial flexibility. Overall, the company’s financial foundation looks thin, and it appears dependent on the capital markets or new deals to fund its plans rather than on internal resources.

Cash Flow

Cash Flow Cash flows from operations have been consistently negative, reflecting a company that spends on running and developing the business but does not yet bring in cash from customers. There is essentially no visible investment in hard assets, which fits with a largely digital and intellectual‑property‑driven model. The combination of ongoing cash burn and a small cash balance raises questions about how frequently the company may need to raise additional funding to keep executing its strategy.

Competitive Edge

Competitive Edge Hyperion DeFi is trying to carve out a very unusual niche: a public company whose core asset is a large position in a single DeFi token and deep participation in one blockchain ecosystem, while still retaining a legacy medical‑device platform. Its competitive edge rests on being an early and visible public gateway into the Hyperliquid/HYPE ecosystem, with validator operations, staking, and structured agreements like HAUS that aim to turn token ownership into recurring fee income. This first‑mover position and its partnerships create a potential moat, but the business is highly exposed to the fortunes of one token and one network, and it must also compete with purely crypto‑native players and traditional financial firms that may enter the space. The dual identity—DeFi plus ophthalmic device—offers diversification in theory, but also adds execution complexity and brand confusion.

Innovation and R&D

Innovation and R&D On the DeFi side, the company is innovating mainly in how it structures and monetizes its token holdings—through validator operations, liquid staking arrangements, and the HAUS platform that lets partners use its tokens in return for a share of trading fees. These are financial and architectural innovations more than lab‑style R&D, but they are still early and unproven at scale. On the healthcare side, the Optejet device remains a genuine piece of medical technology with prior development work behind it, and the current focus appears to be on verification, validation, and finding licensing or commercialization partners rather than heavy new research. Together, these efforts offer multiple potential paths to future revenue, but each path—DeFi products and medical‑device partnerships—faces its own regulatory, technical, and adoption hurdles.

Summary

Hyperion DeFi is in the middle of a major strategic transformation, shifting from a small, loss‑making ophthalmic device company into a hybrid entity that combines a specialized DeFi treasury strategy with a legacy medical technology asset. Financially, it is still at an early, fragile stage: almost no revenue, recurring losses, negative equity, and ongoing cash burn. Strategically, its strength lies in its first‑of‑its‑kind positioning around the Hyperliquid ecosystem, its active on‑chain participation, and its attempt to turn token ownership into structured, recurring income streams through platforms like HAUS. The Optejet device adds an additional, unrelated option for future value but also increases complexity. Overall, this is a high‑uncertainty, high‑execution‑risk story that depends heavily on successful commercialization of new DeFi structures, the health of a single blockchain ecosystem, and the company’s ability to secure partners and capital while it remains pre‑revenue.

NEWS

September 29, 2025 · 8:00 AM UTC

Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer

Read more

September 25, 2025 · 8:00 AM UTC

Hyperion DeFi Adds $10M in HYPE to its Treasury Holdings

Read more

September 16, 2025 · 8:00 AM UTC

Hyperion DeFi Enters Into First HAUS Agreement With Proprietary Trading Firm Credo

Read more